Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.54 |
| ▸ | HTR1D | P28221 | 1/20 | 0.54 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.45 |
| ▸ | PTGIR | P43119 | 1/20 | 0.45 |
| ▸ | CFB | P00751 | 1/20 | 0.45 |
| ▸ | WDR5 | P61964 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561022 | 0.88 | HTR1D (0.55) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL8139996 | 0.85 | HTR1D (0.52) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL12139511 | 0.82 | WDR5 (0.47) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL560405 | 0.81 | LMNA (0.71) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL560777 | 0.81 | LMNA (0.56) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL6670018 | 0.81 | LMNA (0.54) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| Iodide SCHEMBL16227866 | 0.80 | LMNA (0.59) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL8146712 | 0.80 | SMN1; SMN2 (0.53) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL10022889 | 0.80 | LMNA (0.62) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL8148008 | 0.80 | LMNA (0.52) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954807-A | Method for preparing dihydrochloride of anticancer agent | 昂克希尔迪克斯有限公司 | 2025-05-09 | — | — | CN | claimed |
| US-20150224080-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2015-08-13 | — | — | US | claimed |
| US-9034910-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2015-05-19 | — | — | US | claimed |
| US-20120165380-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2012-06-28 | — | — | US | claimed |
| US-20120035235-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2012-02-09 | — | — | US | claimed |
| US-8071636-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-12-06 | — | — | US | claimed |
| CN-102099032-A | Methods of treating alpha adrenergic mediated conditions | ALLERGAN INC | 2011-06-15 | — | — | CN | claimed |
| EP-2303264-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | Allergan, Inc. (US) | 2011-04-06 | — | — | EP | claimed |
| WO-2009152052-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-17 | — | — | WO | claimed |
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | claimed |
| US-12630550-B2 | Pharmacophore for trail induction | THE SCRIPPS RESEARCH INSTITUTE (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250241920-A1 | 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E] PYRIMIDIN-5 (1 H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPY | CHIMERIX, INC. (US) | 2025-07-31 | — | — | US | disclosed |
| EP-4565237-A1 | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF GLIOMA | Chimerix, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| CN-119997956-A | Pharmaceutical composition and use thereof for treating glioma | 奇默里克斯公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119954807-A | Method for preparing dihydrochloride of anticancer agent | 昂克希尔迪克斯有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-7186737-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-06 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630550-B2 | Pharmacophore for trail induction | STAT3, STAT1, STAT4 | LMNA 3925/4885GAA 4860/4885APOBEC3A 2647/4885 |
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2C, ADRA2A | LMNA 1467/4885GAA 751/4885APOBEC3A 3206/4885 |
| US-20150224080-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | LMNA 1464/4885GAA 733/4885APOBEC3A 3241/4885 |
| US-20250241920-A1 | 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E] PYRIMIDIN-5 (1 H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPY | TPMT, PAICS, THPO | LMNA 3547/4885GAA 1262/4885APOBEC3A 3528/4885 |
| US-20120035235-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2C, ADRA2A | LMNA 1467/4885GAA 751/4885APOBEC3A 3206/4885 |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | F2, TFPI, PLG | LMNA 101/4885GAA 1569/4885APOBEC3A 1565/4885 |
| US-20120165380-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | LMNA 1464/4885GAA 733/4885APOBEC3A 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.